Publication Cover
AIDS Care
Psychological and Socio-medical Aspects of AIDS/HIV
Volume 29, 2017 - Issue 7
612
Views
22
CrossRef citations to date
0
Altmetric
Original Articles

“It’s about my life”: facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa

ORCID Icon, , ORCID Icon, & ORCID Icon
Pages 936-942 | Received 19 Jun 2015, Accepted 05 Jan 2017, Published online: 01 Feb 2017

References

  • Akolo, C., Adetifa, I., Shepperd, S., & Volmink, J. (2010). Treatment of latent tuberculosis infection in HIV infected persons. The Cochrane Database of Systematic Reviews (1), CD000171. doi:10.1002/14651858.CD000171.pub3
  • Chehab, J. C., Vilakazi-Nhlapo, K., Vranken, P., Peters, A., & Klausner, J. D. (2012). Survey of isoniazid preventive therapy in South Africa, 2011. The International Journal of Tuberculosis and Lung Disease, 16(7), 903–907. doi:10.5588/ijtld.11.0722
  • Codecasa, L. R., Murgia, N., Ferrarese, M., Delmastro, M., Repossi, A. C., Casali, L., … Raviglione, M. C. (2013). Isoniazid preventive treatment: Predictors of adverse events and treatment completion. The International Journal of Tuberculosis and Lung Disease, 17(7), 903–908. doi:10.5588/ijtld.12.0677
  • Daftary, A., Padayatchi, N., & O’Donnell, M. (2014). Preferential adherence to antiretroviral therapy over tuberculosis treatment: A qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Global Public Health, 9(9), 1107–1116. doi:10.1080/17441692.2014.934266
  • Durovni, B., Cavalcante, S. C., Saraceni, V., Vellozo, V., Israel, G., King, B. S., … Golub, J. E. (2010). The implementation of isoniazid preventive therapy in HIV clinics: The experience from the TB/HIV in Rio (THRio) study. AIDS, 24(Suppl 5), S49–S56. doi:10.1097/01.aids.0000391022.95412.a6
  • Grant, A. D., Mngadi, K. T., van Halsema, C. L., Luttig, M. M., Fielding, K. L., & Churchyard, G. J. (2010). Adverse events with isoniazid preventive therapy: Experience from a large trial. AIDS, 24(Suppl 5), S29–S36. doi:10.1097/01.aids.0000391019.10661.66
  • Gust, D. A., Mosimaneotsile, B., Mathebula, U., Chingapane, B., Gaul, Z., Pals, S. L., & Samandari, T. (2011). Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS One, 6(4), e18435. doi:10.1371/journal.pone.0018435
  • van Halsema, C. L., Fielding, K. L., Chihota, V. N., Russell, E. C., Lewis, J. J., Churchyard, G. J., & Grant, A. D. (2010). Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS, 24(7), 1051–1055. doi:10.1097/QAD.0b013e32833849df
  • KwaZulu-Natal uMzinyathi District Profile. (2012). KwaZulu-Natal South Africa.
  • Launch of 2013 Isoniazid Preventive Therapy Guidelines. (2013). Paper presented at the 6th South African AIDS Conference, Durban, South Africa.
  • Lester, R., Hamilton, R., Charalambous, S., Dwadwa, T., Chandler, C., Churchyard, G. J., & Grant, A. D. (2010). Barriers to implementation of isoniazid preventive therapy in HIV clinics: A qualitative study. AIDS, 24(Suppl 5), S45–S48. doi:10.1097/01.aids.0000391021.18284.12
  • Makanjuola, T., Taddese, H. B., & Booth, A. (2014). Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: A systematic review of qualitative data. PLoS One, 9(2), e87166. doi:10.1371/journal.pone.0087166
  • Mindachew, M., Deribew, A., Tessema, F., & Biadgilign, S. (2011). Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. BMC Public Health, 11, 213. doi:10.1186/1471-2458-11-916
  • Munro, S. A., Lewin, S. A., Smith, H. J., Engel, M. E., Fretheim, A., & Volmink, J. (2007). Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Medicine, 4(7), e238. doi:10.1371/journal.pmed.0040238
  • National Tuberculosis Management Guidelines. (2014). National tuberculosis management guidelines. Pretoria: Department of Health, South Africa.
  • Ngamvithayapong, J., Uthaivoravit, W., Yanai, H., Akarasewi, P., & Sawanpanyalert, P. (1997). Adherence to tuberculosis preventive therapy among HIV-infected persons in chiang Rai, Thailand. AIDS, 11(1), 107–112. doi: 10.1097/00002030-199701000-00016
  • Oni, T., Tsekela, R., Kwaza, B., Manjezi, L., Bangani, N., Wilkinson, K. A., … Wilkinson, R. J. (2012). A recent HIV diagnosis is associated with non-completion of Isoniazid preventive therapy in an HIV-infected cohort in Cape Town. PLoS One, 7(12), e52489. doi:10.1371/journal.pone.0052489
  • Pope, C., Ziebland, S., & Mays, N. (2000). Qualitative research in health care: Analysing qualitative data. BMJ, 320(7227), 114–116. doi: 10.1136/bmj.320.7227.114
  • Rowe, K. A., Makhubele, B., Hargreaves, J. R., Porter, J. D., Hausler, H. P., & Pronyk, P. M. (2005). Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: Implications for antiretroviral delivery in resource-poor settings? The International Journal of Tuberculosis and Lung Disease, 9(3), 263–269.
  • Rutherford, M. E., Ruslami, R., Maharani, W., Yulita, I., Lovell, S., Van Crevel, R., … Hill, P. C. (2012). Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation. BMC Research Notes, 5, 7. doi:10.1186/1756-0500-5-7
  • Szakacs, T. A., Wilson, D., Cameron, D. W., Clark, M., Kocheleff, P., Muller, F. J., & McCarthy, A. E. (2006). Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infectious Diseases, 6, 1009. doi:10.1186/1471-2334-6-97
  • The national antenatal sentinel HIV and Syphilis prevalence survey, South Africa. (2010). Pretoria: National Department of Health. Retrieved from http://www.gov.za/sites/www.gov.za/files/hiv_aids_survey_0.pdf
  • World Health Organization. (2007). Global tuberculosis report 2014 (Report No. WHO/HTM/TB/2014.08). Geneva: Author. Retrieved from http://www.who.int/tb/publications/2014/en/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.